Top News

BridgeBio Attruby medicine box for transthyretin amyloid cardiomyopathy

INSIGHTS

30 Oct 2025

BridgeBio’s Strategy Shift Tests the Economics of Rare Disease

BridgeBio leans on its ATTR-CM launch to push late-stage assets while facing competition, pricing pressure, and questions about demand dur...

Exterior AbbVie sign in front of a metal security fence and industrial building during winter conditions

PARTNERSHIPS

23 Jun 2026

Why AbbVie Just Spent $10.9B on Apogee

Newborn baby with hearing test and forehead monitoring equipment in a clinical setting

TECHNOLOGY

13 May 2026

Born Deaf No More: FDA Greenlights Historic Treatment

Latest News

Why AbbVie Just Spent $10.9B on Apogee

PARTNERSHIPS

23 Jun 2026

AbbVie agreed to acquire Apogee Therapeutics for $10.9B, adding late-stage IL-13 and TSLP assets targeting atopic dermatitis and asthma

RNA strand illustration representing personalised antisense therapy development

INNOVATION

1 Feb 2025

Inside the Push to Personalize RNA Medicine

Tailored antisense drugs move from concept to clinic as researchers and companies test faster models for ultra-rare conditions

8 9

topics on the agenda

A RADICALLY NEW ERA OF PATIENT-DRIVEN THERAPEUTICS

Day 1: MONDAY, JULY 13, 2026

09:00 - 09:25

DESIGNED WITH PATIENTS, FOR PATIENTS: RISE UP SICKLE CELL DISEASE CLINICAL PROGRAM

Day 1: MONDAY, JULY 13, 2026

09:30 - 09:55

PANEL DISCUSSION ON PATIENT ADVOCACY AS INFRASTRUCTURE FOR RARE DISEASE DEVELOPMENT

Day 1: MONDAY, JULY 13, 2026

11:00 - 11:30

View more topics

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.